Abstract
Systemic therapy options have emerged for treatment of progressive, radioiodine-refractory differentiated thyroid carcinoma. Approved therapies that target tumor angiogenesis, lenvatinib and sorafenib, improve progression-free survival and, in an older subset, lenvatinib can prolong overall survival. Treatments based on targeting specific somatic genetic alterations are also available, which potentially also may prolong progression-free survival but are not yet approved for use by the Food and Drug Administration for this specific disease. More novel approaches that may benefit select patients include resensitization therapies that allow further radioiodine utilization and new immunotherapy concepts.
Original language | English (US) |
---|---|
Pages (from-to) | 253-268 |
Number of pages | 16 |
Journal | Endocrinology and Metabolism Clinics of North America |
Volume | 48 |
Issue number | 1 |
DOIs | |
State | Published - Mar 2019 |
Keywords
- Angiogenesis
- Immunotherapy
- MEK kinases
- Mitogen-activated protein kinases
- Protooncogene protein TRK
- Receptor tyrosine kinase RET
- TOR serine-threonine kinases
- Thyroid neoplasms
ASJC Scopus subject areas
- Endocrinology, Diabetes and Metabolism
- Endocrinology